Literature DB >> 29981149

Survival from childhood cancers in Eastern Africa: A population-based registry study.

W Yvonne Joko-Fru1, D Maxwell Parkin1, Margaret Borok2, Eric Chokunonga2, Anne Korir3, Sarah Nambooze4, Henry Wabinga4, Biying Liu1, Cristina Stefan5.   

Abstract

Cancers occurring in children in Africa are often underdiagnosed, or at best diagnosed late. As a result, survival is poor, even for cancers considered 'curable'. With limited population-level data, understanding the actual burden and survival from childhood cancers in Africa is difficult. In this study, we aimed at providing survival estimates for the most common types of cancers affecting children aged 0-14 years, in three population-based Eastern African registries; Harare, Zimbabwe (Kaposi sarcoma, Wilms tumour (WT), non-Hodgkin lymphoma (NHL), retinoblastoma, and acute lymphocytic leukaemia (ALL)), Kampala, Uganda (Burkitt lymphoma, Kaposi sarcoma, WT, and retinoblastoma), and Nairobi, Kenya (ALL, retinoblastoma, WT, Burkitt lymphoma, and Hodgkin lymphoma). We included cases diagnosed within the years 1998-2009 and followed up till the end of 2011. We estimated the observed and relative survival at 1, 3, and 5 years after diagnosis. We studied 627 individual patient records. Median follow-up ranged from 2.2 months for children with Kaposi sarcoma in Harare to 30.2 months for children with ALL in Nairobi. The proportion of children lost to follow-up was highest in the first year after diagnosis. In Harare and Kampala, the 5-year relative survival was <46% for all cancer types. The 5-year relative survival was best for children in Nairobi, though with wider confidence intervals. Survival from childhood cancers in Africa is still poor, even for cancers with good prognosis and potential for cure. Supporting cancer detection, treatment, and registration activities could help improve survival chances for children with cancers in Africa.
© 2018 UICC.

Entities:  

Keywords:  Africa; cancer; children; population-based registry; survival

Mesh:

Year:  2018        PMID: 29981149     DOI: 10.1002/ijc.31723

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Investigating Wilms' Tumours Worldwide: A Report of the OxPLORE Collaboration-A Cross-Sectional Observational Study.

Authors:  K Ford; S Gunawardana; E Manirambona; G S Philipoh; B Mukama; A Kanyamuhunga; P Cartledge; M J Nyoni; D Mwaipaya; J Mpwaga; Z Bokhary; T Scanlan; T Heinsohn; H Hathaway; R Mansfield; S Wilson; K Lakhoo
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

2.  Nephroblastoma Treatment and Outcomes in a Low-Income Setting.

Authors:  Cyprien Shyirambere; Chandler Villaverde; Cam Nguyen; Deogratias Ruhangaza; Aline Umwizerwa; Oscar Nsanzimana; Louis Mujyuwisha; Esperance Iradukunda; Lawrence N Shulman; Leslie Lehmann
Journal:  JCO Glob Oncol       Date:  2022-07

3.  Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.

Authors:  Bruno M Grande; Daniela S Gerhard; Aixiang Jiang; Nicholas B Griner; Jeremy S Abramson; Thomas B Alexander; Hilary Allen; Leona W Ayers; Jeffrey M Bethony; Kishor Bhatia; Jay Bowen; Corey Casper; John Kim Choi; Luka Culibrk; Tanja M Davidsen; Maureen A Dyer; Julie M Gastier-Foster; Patee Gesuwan; Timothy C Greiner; Thomas G Gross; Benjamin Hanf; Nancy Lee Harris; Yiwen He; John D Irvin; Elaine S Jaffe; Steven J M Jones; Patrick Kerchan; Nicole Knoetze; Fabio E Leal; Tara M Lichtenberg; Yussanne Ma; Jean Paul Martin; Marie-Reine Martin; Sam M Mbulaiteye; Charles G Mullighan; Andrew J Mungall; Constance Namirembe; Karen Novik; Ariela Noy; Martin D Ogwang; Abraham Omoding; Jackson Orem; Steven J Reynolds; Christopher K Rushton; John T Sandlund; Roland Schmitz; Cynthia Taylor; Wyndham H Wilson; George W Wright; Eric Y Zhao; Marco A Marra; Ryan D Morin; Louis M Staudt
Journal:  Blood       Date:  2019-01-07       Impact factor: 25.476

4.  Long Noncoding RNA HEIH Promotes Proliferation, Migration and Invasion of Retinoblastoma Cells Through miR-194-5p/WEE1 Axis.

Authors:  Sheng Gao; Qingxia Chu; Xia Liu; Xia Zhao; Libao Qin; Guoliang Li; Qinghuai Liu
Journal:  Onco Targets Ther       Date:  2020-11-23       Impact factor: 4.147

5.  The outcome and cost of a capacity-building training programme on the early recognition and referral of childhood cancer for healthcare workers in North-West Cameroon.

Authors:  Glenn Mbah Afungchwi; Peter Bernard Hesseling; Francine Kouya; Sam A Enow; Mariana Kruger
Journal:  Nurs Open       Date:  2020-08-26

6.  Population-Based Cancer Registration in Sub-Saharan Africa: Its Role in Research and Cancer Control.

Authors:  Abidemi Emmanuel Omonisi; Biying Liu; Donald Maxwell Parkin
Journal:  JCO Glob Oncol       Date:  2020-11

7.  Net survival differences of breast cancer between stages at diagnosis and age groups in the east coast region of West Malaysia: a retrospective cohort study.

Authors:  Tengku Muhammad Hanis; Najib Majdi Yaacob; Suhaily Mohd Hairon; Sarimah Abdullah
Journal:  BMJ Open       Date:  2021-05-18       Impact factor: 2.692

Review 8.  Pediatric Solid Tumors in Resource-Constrained Settings: A Review of Available Evidence on Management, Outcomes, and Barriers to Care.

Authors:  Nicholas H Carter; Andrew H Avery; Jaime Libes; Harold N Lovvorn; Erik N Hansen
Journal:  Children (Basel)       Date:  2018-10-23

9.  A hospital-based cancer registry in Luanda, Angola: the Instituto Angolano de Controlo do Cancer (IACC) Cancer registry.

Authors:  Fernando Miguel; Maria José Bento; Gonçalo Forjaz de Lacerda; Elisabete Weiderpass; Lúcio Lara Santos
Journal:  Infect Agent Cancer       Date:  2019-11-08       Impact factor: 2.965

10.  Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana.

Authors:  Cecilia Smith-Togobo; Mette Ø Pedersen; Steffen G Jensen; Babatunde Duduyemi; Richard K Gyasi; Michael F Ofori; Vivian Paintsil; Lorna Renner; Peter Nørgaard; Lars Hviid
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.